Integrated Oncology provides more than just a test result.
Integrated Oncology is a leader in personalized medicine and companion diagnostics with a strong focus on molecular oncology and genetics. And every day we deliver, with great accuracy, information connectivity and high speed. Whatever your role in the patient care continuum, the reliable services of Integrated Oncology will save you time and optimize your performance.
What's New
BRAF Gene Mutation Assay, Melanoma, the first FDA-approved IVD for BRAF mutation detection in melanoma
PATHways custom reporting solutions for pathologists
CEBPA, c-KIT, and NPM1 mutation analysis for risk prognosis in acute myelogenous leukemia (AML)
MPL Mutation Analysis for primary myelofibrosis and essential thrombocythemia
PIK3CA Mutation Analysis. Mutations in PIK3CA may indicate prognosis and drug response in liver, colorectal, and breast cancer
KRAS and BRAF mutation status has been shown to provide prognostic and potentially predictive information for patients considered for anti-EGFR monoclonal antibody therapies
PNH Evaluation by flow cytometry: High-sensitivity flow allows for detection of smaller PNH clones than standard flow cytometry
Events & Education
March 19-21
USCAP Annual Meeting
Vancouver, BC
June 2-4
ASCO Annual Meeting
Chicago, IL
Contact Us | Careers | Site Map Integrated Oncology is a business unit of Accupath Diagnostics Laboratories, Inc., a wholly-owned subsidiary of Laboratory Corporation of America Holdings.
© 2012 Laboratory Corporation of America® Holdings. All rights reserved.